Tiziana Life Sciences Doses First Patient in MSA Trial
Ticker: TLSA · Form: 6-K · Filed: Aug 14, 2025 · CIK: 1723069
Sentiment: neutral
Topics: clinical-trial, drug-development, neurology
TL;DR
Tiziana Life Sciences dosed first patient in MSA Phase 2a trial at Brigham and Women's.
AI Summary
Tiziana Life Sciences Ltd. announced on August 14, 2025, that the first participant has been enrolled and dosed in its Phase 2a clinical trial. This trial, taking place at Brigham and Women's Hospital, will evaluate intranasal foralumab for patients diagnosed with Multiple System Atrophy (MSA).
Why It Matters
This marks a significant step in evaluating a potential new treatment for Multiple System Atrophy, a rare and debilitating neurological disorder.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, with potential for delays, unexpected results, or regulatory hurdles.
Key Players & Entities
- Tiziana Life Sciences Ltd (company) — Registrant
- Brigham and Women's Hospital (company) — Clinical trial site
- Multiple System Atrophy (MSA) (condition) — Disease being studied
- foralumab (drug) — Investigational drug
FAQ
What is the primary goal of the Phase 2a clinical trial?
The primary goal is to evaluate intranasal foralumab in patients living with Multiple System Atrophy (MSA).
Where is the Phase 2a clinical trial being conducted?
The trial is being conducted at Brigham and Women's Hospital.
What specific drug is being tested in the trial?
The drug being tested is intranasal foralumab.
What condition is the trial focused on treating?
The trial is focused on treating Multiple System Atrophy (MSA).
On what date did Tiziana Life Sciences announce this trial update?
Tiziana Life Sciences announced this trial update on August 14, 2025.
Filing Stats: 320 words · 1 min read · ~1 pages · Grade level 14.2 · Accepted 2025-08-14 08:30:01
Filing Documents
- ea0253255-6k_tiziana.htm (6-K) — 14KB
- ea025325501ex99-1_tiziana.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-076077.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TIZIANA LIFE SCIENCES LTD Date: August 14, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 2 EXHIBIT INDEX Exhibit No. Description 99.1 Tiziana Life Sciences LTD Press Release, dated August 14, 2025 3